AVIR
Atea Pharmaceuticals Inc

3,059
Mkt Cap
$482.02M
Volume
480,831.00
52W High
$6.45
52W Low
$2.46
PE Ratio
-3.10
AVIR Fundamentals
Price
$6.13
Prev Close
$6.05
Open
$6.04
50D MA
$4.38
Beta
0.76
Avg. Volume
484,217.19
EPS (Annual)
-$1.94
P/B
1.72
Rev/Employee
$0.00
$10.05
Loading...
Loading...
News
all
press releases
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month High - Here's Why
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 1-Year High - What's Next...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Atea Pharmaceuticals Q4 Earnings Call Highlights
Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its...
MarketBeat·12d ago
News Placeholder
Atea Pharmaceuticals (NASDAQ:AVIR) Posts Earnings Results, Misses Expectations By $0.08 EPS
Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus...
MarketBeat·12d ago
News Placeholder
Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings
read more...
Benzinga·13d ago
News Placeholder
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday
Atea Pharmaceuticals (NASDAQ:AVIR) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 5. (View Earnings Report at...
MarketBeat·20d ago
News Placeholder
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 2% - Here's What Happened
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 2% - Here's Why...
MarketBeat·1mo ago
News Placeholder
Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 2% - Time to Sell?
Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 2% - Should You Sell...
MarketBeat·1mo ago
News Placeholder
Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference
Atea Pharmaceuticals (NASDAQ:AVIR) used its presentation at the 44th Annual JPMorgan Healthcare Conference to provide updates on its global Phase 3 program for hepatitis C (HCV) and to outline early...
MarketBeat·2mo ago
News Placeholder
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4% - Here's What Happened
Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 1.4% - Here's What Happened...
MarketBeat·3mo ago
News Placeholder
Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 1.9% - Should You Sell?
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.9% - Should You Sell...
MarketBeat·3mo ago
<
1
2
...
>

Latest AVIR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.